ArticleEBioMedicine2026
Investigating the role of baseline gut Akkermansia muciniphila and its co-metabolite palmitoleic acid in BCG vaccine efficacy: a preclinical study.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBacillus Calmette-Guérin (BCG) is the only vaccine for tuberculosis (TB) and remains the most effective means of prevention; however, its effectiveness in humans is highly variable with unknown mechanism.
methodsUsing microbiota transplantation and multi-omics strategies (16S rRNA sequencing, metabolomics, proteomics) in mouse models, we investigated the effect of pre-vaccination gut microbiota composition on BCG vaccine efficacy. Furthermore, key findings were validated in human datasets.
findingsBaseline abundance of gut microbiota, especially Akkermansia muciniphila, significantly affects BCG vaccine efficacy. Increasing the baseline levels of A. muciniphila in the gut before vaccination reduced the BCG vaccine responses, resulting in impaired protection against Mycobacterium tuberculosis (Mtb) infection in mice. A. muciniphila-contributed gut co-metabolite palmitoleic acid inhibits the vaccine responses of BCG. Palmitoleic acid acts on vaccine response through the mediation of effector protein MptpB of BCG and identified that MptpB-mediated inhibition of actin cytoskeleton remodelling to activate BCG vaccine responses is required for palmitoleic acid to regulate the efficacy of BCG vaccination. Inhibition of MptpB or actin cytoskeleton remodelling blocks the effects of higher baseline abundance of A. muciniphila on the efficacy of BCG vaccination. Analyses of human datasets provided hypothesis-generating support for these findings. Mechanistically, the higher baseline levels of gut A. muciniphila and its metabolite palmitoleic acid inhibit BCG vaccine efficacy by suppressing MptpB-mediated actin cytoskeleton remodelling.
interpretationThese results show that pre-vaccination differences in gut microbiota composition are a factor accounting for high variation in vaccine effectiveness. Stratifying by baseline gut microbiota profile and metabolism may represent a strategy to enhance future vaccine efficacy.
fundingGuang Dong Cheung Kong Philanthropy Foundation, Guangzhou key R & D project, National Natural Science Foundation of China, Key laboratory start-up project (Sixth Affiliated Hospital of Sun Yat-sen University), Guangdong Basic and Applied Basic Research Foundation, Guangzhou Basic and Applied Basic Research Foundation, Doctoral Initial Funding of Guangdong Medical University, Shenzhen Medical Research Fund, Discipline construction project of Guangdong Medical University, Project of Songshan Lake Innovation Center of Medicine & Engineering of Guangdong Medical University.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.